Pharma Mar (PHM) Stock Overview
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for PHM from our risk checks.
PHM Community Fair Values
Create NarrativeSee what 33 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharma Mar, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €73.65 |
| 52 Week High | €105.20 |
| 52 Week Low | €64.00 |
| Beta | 0.43 |
| 1 Month Change | -10.29% |
| 3 Month Change | 5.97% |
| 1 Year Change | -17.34% |
| 3 Year Change | 125.23% |
| 5 Year Change | -6.70% |
| Change since IPO | 55.38% |
Recent News & Updates
Analyst Estimates: Here's What Brokers Think Of Pharma Mar, S.A. (BME:PHM) After Its Half-Yearly Report
Last week saw the newest half-yearly earnings release from Pharma Mar, S.A. ( BME:PHM ), an important milestone in the...
PHM: Future Cancer Trial Progress And New Lung Cancer Approvals Will Matter
Analysts have raised their 12-month price target for Pharma Mar from €75 to €90, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and expected future P/E following new Street research coverage. What’s in the News for Pharma Mar Pharma Mar started a Phase 1/2 clinical trial of PM54 in combination with pembrolizumab for previously treated patients with advanced solid tumors, following US FDA IND approval in December 2025.Recent updates
Analyst Estimates: Here's What Brokers Think Of Pharma Mar, S.A. (BME:PHM) After Its Half-Yearly Report
Last week saw the newest half-yearly earnings release from Pharma Mar, S.A. ( BME:PHM ), an important milestone in the...PHM: Future Cancer Trial Progress And New Lung Cancer Approvals Will Matter
Analysts have raised their 12-month price target for Pharma Mar from €75 to €90, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and expected future P/E following new Street research coverage. What’s in the News for Pharma Mar Pharma Mar started a Phase 1/2 clinical trial of PM54 in combination with pembrolizumab for previously treated patients with advanced solid tumors, following US FDA IND approval in December 2025.
PHM: First Line Lung Cancer Maintenance Approvals Will Support Medium Term Upside
Analysts have reset their 12 month price target for Pharma Mar to €125, reflecting updated assumptions around a slightly higher discount rate, modestly stronger projected revenue growth and profit margins, and a marginally lower future P/E, while citing supportive recent Street research coverage. What’s in the News for Pharma Mar Zepzelca (lurbinectedin) did not meet the primary overall survival endpoint in the Phase III LAGOON confirmatory trial for relapsed metastatic small cell lung cancer, according to Jazz Pharmaceuticals and Pharma Mar.PHM: Asia Pacific Lung Cancer Approvals Will Drive Medium Term Upside Potential
Analysts have maintained their €125 price target on Pharma Mar, citing BTIG's recent bullish initiation and updated assumptions for slightly higher revenue, profit margins, and a modestly lower discount rate and P/E multiple. What's in the News European Commission approves Zepzelca (lurbinectedin) with atezolizumab (Tecentriq) as first-line maintenance therapy for adult patients with extensive-stage small cell lung cancer whose disease has not progressed after standard induction therapy, following a positive opinion from the EMA, based on the phase 3 IMforte trial (source: company announcement).PHM: Asia Pacific Lung Cancer Expansion Will Support Medium Term Upside Potential
Analysts have raised their price target on Pharma Mar from €118 to €125, citing new research that reflects updated assumptions on growth, profitability and future P/E expectations following fresh coverage with a bullish stance. Analyst Commentary Recent Street research coverage reflects a confident tone around Pharma Mar, with bullish analysts pointing to updated assumptions on growth, profitability and future P/E expectations as key supports for higher valuation ranges.Pharma Mar's (BME:PHM) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Pharma Mar, S.A.'s ( BME:PHM ) stock hasn't moved much. We did...There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Pharma Mar, S.A.'s ( BME:PHM ) robust earnings report didn't manage to move the market for its stock. We did some...Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Pharma Mar, S.A. ( BME:PHM ) last week reported its latest third-quarter results, which makes it a good time for...Is Pharma Mar (BME:PHM) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)
It's not a stretch to say that Pharma Mar, S.A.'s ( BME:PHM ) price-to-sales (or "P/S") ratio of 7.4x right now seems...Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.80 on 27th...Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
Pharma Mar, S.A. ( BME:PHM ) will increase its dividend from last year's comparable payment on the 27th of June to...
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit
The latest earnings release from Pharma Mar, S.A. ( BME:PHM ) disappointed investors. Our analysis found several...There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump
The Pharma Mar, S.A. ( BME:PHM ) share price has done very well over the last month, posting an excellent gain of 27...Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 55% gain in the last month alone. The...Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 27% gain in the last month alone...Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.65 on 14th...Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
Pharma Mar, S.A. ( BME:PHM ) shareholders would be excited to see that the share price has had a great month, posting a...Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Last week, you might have seen that Pharma Mar, S.A. ( BME:PHM ) released its annual result to the market. The early...Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pharma Mar fair value estimate is €52.37 Pharma Mar is...Shareholder Returns
| PHM | ES Biotechs | ES Market | |
|---|---|---|---|
| 7D | -3.7% | 1.1% | 0.6% |
| 1Y | -17.3% | 18.4% | 27.0% |
Return vs Industry: PHM underperformed the Spanish Biotechs industry which returned 18.4% over the past year.
Return vs Market: PHM underperformed the Spanish Market which returned 27% over the past year.
Price Volatility
| PHM volatility | |
|---|---|
| PHM Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 2.9% |
| 10% most volatile stocks in ES Market | 6.2% |
| 10% least volatile stocks in ES Market | 0.5% |
Stable Share Price: PHM has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: PHM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 505 | Jose Fernandez Sousa-Faro | www.pharmamar.com |
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma.
Pharma Mar, S.A. Fundamentals Summary
| PHM fundamental statistics | |
|---|---|
| Market cap | €1.30b |
| Earnings (TTM) | €56.13m |
| Revenue (TTM) | €218.64m |
Is PHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHM income statement (TTM) | |
|---|---|
| Revenue | €218.64m |
| Cost of Revenue | €14.47m |
| Gross Profit | €204.17m |
| Other Expenses | €148.05m |
| Earnings | €56.13m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.24 |
| Gross Margin | 93.38% |
| Net Profit Margin | 25.67% |
| Debt/Equity Ratio | 17.2% |
How did PHM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/18 17:45 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharma Mar, S.A. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Kambiz Yazdi | BTIG |